CDT Equity Registers 16.8M Shares for Resale, Including J.J. Astor Conversion Shares and Sarborg Consideration
CDT is trading near its 52-week low of $0.157 (6.5% above the low) on elevated volume (9.4× avg).
Summary
CDT Equity registered 16.8M shares for resale — nearly 87% of shares outstanding — including 3.9M shares to lender J.J. Astor under convertible notes with a VWAP-based conversion formula, and 650,000 shares already issued to Sarborg under an amended acquisition agreement.
Key Events · Financing and Capital Events · CDT
-
16.8M Shares Registered for Resale
The prospectus registers 16,825,644 shares for resale by Selling Stockholders, representing approximately 87% of the 19,268,220 shares outstanding as of September 14, 2026.
-
J.J. Astor Conversion Shares
3,888,875 shares are registered for J.J. Astor & Co. — 365,750 warrant shares and 3,523,125 conversion shares under the amended Notes. The conversion price is the greater of 70% of the lowest VWAP over 20 trading days or the Nasdaq floor price, with make-whole provisions if the market price falls below the floor.
-
Sarborg Amendment Quantified
The August 31, 2026 amendment to the Sarborg Securities Purchase Agreement converts $1,750,000 of the $8M cash consideration into 650,000 shares already issued to Sarborg, with minimum $150,000 monthly ATM payments and the balance due May 31, 2027.
-
Going Concern and Cash Position
The prospectus reiterates substantial doubt about the Company's ability to continue as a going concern, with cash of $747K as of June 30, 2026 and a working capital requirement of approximately $21.0M for the next 12 months.
Analysis · CDT · Life Sciences
This prospectus registers 16,825,644 shares for resale by Selling Stockholders — nearly 87% of the 19,268,220 shares currently outstanding. The largest block is 3,888,875 shares to J.J. Astor & Co., the lender under the amended senior secured convertible notes, whose conversion price is tied to a formula based on the lowest VWAP over 20 trading days — a structure that can produce substantial additional dilution if the stock price falls. The filing also discloses the August 31, 2026 Sarborg amendment, which converts $1,750,000 of the $8M cash consideration into 650,000 shares already issued, and requires minimum $150,000 monthly ATM payments through May 31, 2027. Against a backdrop of going-concern warnings, $747K cash as of June 30, 2026, and a stock price of $0.19, the registration makes a massive overhang tradable and signals continued reliance on highly dilutive financing.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 35.4% of the 1137 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.37%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CDT was trading at $0.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $0.16 to $1,778.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.